Open AccessAn Experience of Oseltamivir Phosphate (Tamiflu™) in a Pediatric Patient with Chronic Idiopathic Thrombocytopenic Purpura: A Case Report
Author(s) -
Bülent Alioğlu,
Ayşin Taşar,
Çınar Özen,
Beray Selver,
Yıldız Dallar
Publication year - 2010
Publication title -
pathophysiology of haemostasis and thrombosis
Language(s) - English
Resource type - Journals
eISSN - 1424-8840
pISSN - 1424-8832
DOI - 10.1159/000321379
Subject(s) - oseltamivir , thrombocytopenic purpura , medicine , neuraminidase inhibitor , thrombotic thrombocytopenic purpura , immunology , immune system , platelet , virus , disease , covid-19 , infectious disease (medical specialty)
We report a pediatric patient with chronic idiopathic thrombocytopenic purpura who suffered from an influenza A (H1N1) virus infection. A 13-year-old girl presented with fever, coughing, and generalized petechiae. The influenza A antigen was positive in her pharyngeal aspirate. She was successfully treated with neuraminidase inhibitor oseltamivir phosphate. Her platelet counts progressively increased with oseltamivir phosphate without another blood product or agent. We suggest that oseltamivir phosphate can be used in patients with immune thrombocytopenic purpura who present with influenza virus A infection. We also suggest that oseltamivir phosphate can be effective in patients with immune thrombocytopenic purpura. Large study groups are needed to confirm the relationship between idiopathic thrombocytopenic purpura and neurominidase inhibitors.